Home Newsfeeds Guggenheim Downgrades Relmada Therapeutics to Neutral

Guggenheim Downgrades Relmada Therapeutics to Neutral

Guggenheim analyst Yatin Suneja downgrades Relmada Therapeutics (NASDAQ:RLMD) from Buy to Neutral.

byBenzinga Newsdesk

October 14, 2022

1 minute read

Guggenheim analyst Yatin Suneja downgrades Relmada Therapeutics (NASDAQ:RLMD) from Buy to Neutral.

Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Raises Price Target to $65

By Benzinga Newsdesk

October 3, 5:08 AM

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and raises the price target from $62 to $65.

RCKT

‘Better Than Vegemite On Toast!’ Jim Farley Cheers As Ford Reclaims Australia’s Best-Selling Vehicle Crown After Nearly 30 Years With Ranger

By Ramakrishnan M

January 4, 2:25 AM

Locally designed and engineered Ford Ranger vehicles were sold to 63,356 customers last year, Ford Australia said.

JPMorgan CEO Jamie Dimon Says Inflation ‘Might Not Go Away That Quickly’

By Benzinga Neuro

November 15, 12:32 AM

Dimon's comments followed a recent unexpected drop in consumer price increases, sparking hopes that measures taken by the Federal Reserve to combat inflation are beginning to take effect.

JPM

Hello Group CEO Li Wang Resigns On Health Grounds; Chair Yan Tang Takes Over Reins

By Anusuya Lahiri

October 28, 12:49 PM

Hello Group Inc (NASDAQ:MOMO), a mobile social and entertainment platform in China, disclosed that Li Wang has resigned as…

MOMO

Guggenheim Downgrades Relmada Therapeutics to Neutral

Related Posts

Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Raises Price Target to $65

‘Better Than Vegemite On Toast!’ Jim Farley Cheers As Ford Reclaims Australia’s Best-Selling Vehicle Crown After Nearly 30 Years With Ranger

JPMorgan CEO Jamie Dimon Says Inflation ‘Might Not Go Away That Quickly’

Hello Group CEO Li Wang Resigns On Health Grounds; Chair Yan Tang Takes Over Reins